---
document_datetime: 2025-10-29 13:08:41
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lytgobi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: lytgobi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.336122
conversion_datetime: 2025-12-27 09:48:28.846756
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Lytgobi

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                      |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------|
| Variation type II /  | C.I HUMAN AND VETERINARY MEDICINAL | 18/09/2025                          |                                             | SmPC and PL                      | Section 4.5 Interaction with other medicinal |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000282565   | PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.2, 4.4, 4.5 and 5.2 of the SmPC in order to revise the drug-drug interaction information based on the final results of study TAS-120-110. This is a Phase 1, open-label, fixed-sequence study to assess the effect of futibatinib on P-gp and BCRP and the effect of P-gp inhibition by quinidine on the pharmacokinetics of futibatinib in healthy adult subjects. The Package Leaflet is updated accordingly.   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       |                                                                                                                                                                                                                                                                                                                     |            |     | geometric mean ratios for Cmax and AUCinf were 110% and 113%, respectively, when co- administered in healthy subjects with futibatinib relative to rosuvastatin alone. Therefore, co- administration of futibatinib is not likely to have a clinically relevant effect on the exposure of BCRP substrates. Section 5.2 Pharmacokinetic properties [â€¦] Effect of futibatinib on drug transporters In vitro studies indicated that futibatinib didn't inhibit OAT1, OAT3, OCT2, OATP1B1, OATP1B3, MATE1 or MATE2K at clinically relevant concentrations. Futibatinib is a substrate of P-gp and BCRP in vitro. Inhibition of BCRP is not expected to result in clinically relevant changes in the exposure of futibatinib. Inhibition of P-gp did not result in a clinically relevant effect on futibatinib exposure in vivo (see section 4.5). For more information, please refer to the Summary of Product Characteristics.   |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000291638 | B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - Accepted | 29/08/2025 | N/A |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Variation type IA / EMA/VR/0000290192 | This was an application for a group of variations.                                                                                                                                                                                                                                                                  | 06/08/2025 | N/A |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|